Dockeray 1989.

Methods	Women randomised according to a randomisation code without blinding into 2 treatment groups, MFA and danazol. 1 woman (from MFA group) was withdrawn because of adverse effects. No loss to follow‐up. The duration of the study was 4 menstrual cycles, 2 untreated (control) and 2 with treatment. No power calculation made or ITT analysis
Participants	Ireland 40 women, mean age 37.8 years (range 23–48 years) with normal pelvic organs and no endometrial pathology Inclusion criteria: objective unexplained MBL > 80 mL/cycle (alkaline haematin method), history of excessive menstrual bleeding
Interventions	Group 1: MFA 500 mg 3 times daily for 3–5 days for 2 cycles, n = 19 Group 2: danazol 100 mg twice daily for 60 days for 2 cycles, n = 20
Outcomes	MBL (alkaline haematin method) Number of days bleeding Quality of life (dysmenorrhoea) Adverse events (incidence, severity) Patient acceptability of treatment (prepared to continue Rx?)
Notes	No ITT analysis Baseline comparability done
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Randomisation code
Allocation concealment (selection bias)	Unclear risk	Unclear risk
Blinding (performance bias and detection bias) All outcomes	High risk	No blinding
Incomplete outcome data (attrition bias) All outcomes	Low risk	No dropouts reported; 1 woman was withdrawn because of adverse effects.
Other bias	Low risk	Similar at baseline